Allergan Plc (AGN)

U.S. stock futures rise as investors assess signs of a breakthrough in U.S.-China trade talks; Broadcom falls after saying chip demand has 'bottomed out'; WeWork will list its shares on the Nasdaq; Cloudflare's IPO is priced at $15 a share.

The $79 price target is a 14% upside to Wednesday's closing price.

DUBLIN, Sept. 10, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc...

Aegon today announces that Mike Holliday-Williams (1970, UK) will succeed Adrian Grace (1963, UK) as Chief Executive Officer of Aegon UK.

- Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen

Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.

DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it received U.

Allergan announces it has reached a settlement with two plaintiffs in Ohio in the multi-district federal litigation over opioids.

DUBLIN, Aug. 30, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the Company and its U.

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma

Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.

Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

Net income increases to EUR 618 million reflecting realized gains and lower other charges ● Underlying earnings decrease by 5% to EUR 1,010 million, reflecting lower fee income as a result of lower average asset balances in the US, and investments in the...

EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.

Aegon announces that its Supervisory Board intends to propose the appointment of Lard Friese as Chief Executive Officer to the Annual General Meeting of Shareholders.

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.

- Q2 2019 GAAP Net Revenues of $4.09 Billion -

A timeline of how Botox became one of the most popular medical beauty procedures.

U.S. stock futures rise Tuesday, following Wall Street's worst day of the year, as China attempts to ease trade tensions with the U.S., Walt Disney to report earnings Tuesday; Barneys New York files for bankruptcy protection.

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

While you may think earnings season is winding down, we still got quite a bit left to go ... here are key companies to keep an eye on the week of August 5, 2019.

Aegon has completed the share buyback program announced on June 19, 2019. This program neutralized the dilutive effect of the 2018 final dividend paid in shares.

DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.

Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.